Paclitaxel, topotecan and rituximab: long term outcomes of an effective salvage programme for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma-Reference-Cited by-同舟云学术

Paclitaxel, topotecan and rituximab: long term outcomes of an effective salvage programme for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma

Published:2014-07-08 Issue:2 Volume:167 Page:177-184
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Westin Jason R.¹^ORCID,McLaughlin Peter¹,Romaguera Jorge¹,Hagemeister Fredrick B.¹,Pro Barbara²,Dang Nam H.³,Samaniego Felipe¹,Rodriguez Maria A.¹,Fayad Luis¹,Oki Yasuhiro¹,Fanale Michelle¹,Fowler Nathan¹,Nastoupil Loretta¹,Feng Lei⁴,Loyer Evelyn⁵,Younes Anas⁶

Affiliation:

1. Department of Lymphoma and Myeloma; The University of Texas M. D. Anderson Cancer Center; Houston TX USA

2. Department of Medical Oncology; Thomas Jefferson University; Philadelphia PA USA

3. Division of Hematology and Oncology; University of Florida; Gainesville FL USA

4. Department of Biostatistics; The University of Texas M. D. Anderson Cancer Center; Houston TX USA

5. Division of Diagnostic Imaging; The University of Texas M. D. Anderson Cancer Center; Houston TX USA

6. Lymphoma Service; Memorial Sloan Kettering Cancer Center; New York NY USA

Funder

National Institutes of Health

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.13014/fullpdf

Reference20 articles.

1. New drugs in non-Hodgkin's lymphoma;Arbuck;Annals of Oncology,1997

2. Conventional second-line salvage chemotherapy regimens are not warranted in patients with malignant lymphomas who have progressive disease after first-line salvage therapy regimens;Ardeshna;British Journal of Haematology,2005

3. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas;Cheson;Journal of Clinical Oncology,1999

4. Response to second-line therapy defines the potential for cure in patients with recurrent diffuse large B-cell lymphoma: implications for the development of novel therapeutic strategies;Elstrom;Clinical Lymphoma Myeloma and Leukemia,2010

5. Relapsed/refractory diffuse large B-cell lymphoma;Friedberg;ASH Education Program Book,2011

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Indications for Autologous Stem Cell Transplant;Basics of Hematopoietic Stem Cell Transplant;2023

2. RNA-seq and integrated network analysis reveals the hub genes and key pathway of paclitaxel inhibition on Adriamycin resistant diffuse large B cell lymphoma cells;Bioengineered;2022-03-01

3. An overview on anti-tubulin agents for the treatment of lymphoma patients;Pharmacology & Therapeutics;2020-07

4. New tricks for old drugs: combination of rituximab and two nanoparticle-delivered chemotherapy drugs, albumin-bound paclitaxel and pegylated liposomal doxorubicin, in the treatment of relapsed/refractory diffuse large B cell lymphoma;Leukemia & Lymphoma;2020-06-06

5. Immunopathology and Immunotherapy of Non-Hodgkin Lymphoma;Cancer Immunology;2020